Table 9.

Clinical trials using agents excluding sirolimus and paclitaxel [21].

Tacrolimus	Present I–III	Preliminary Safety Evaluation of Nanoporous Tacrolimus-Eluting Stents
	EVIDENT	The endovascular investigation determining the safety of new tacrolimus-eluting stent grafts.
Everolimus	FUTURE I–IV	First used to underscore the reduction in restenosis with everolimus.
	SPIRITS-FIRST
M-Prednisolone	IMPRESS	Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation.
Dexamethasone	STRIDE	The study of antirestenosis with a BiodivYsio dexamethasone-eluting stent.
	EMPEROR	Evaluation of the 9α-F-16 methylprednisolone (dexamethasone)-eluting stent on the reduction of restenosis.
	DESIRE	Dexamethasone-eluting stent, Italian registry.
	SAFE	Sorin and aspirin following elective stenting.
Mycophenolic acid	IMPACT	Inhibition with MPA of a coronary restenosis trial.
Batimastat	BATMAN	BiodivYsio batimastat SV stent versus balloon angioplasty for the reduction of restenosis in small coronary arteries.
	BRILLIANT	Batimastat (BB-94) antirestenosis trial utilizing the BiodivYsio local drug delivery PC stent.
Actinomycin	ACTION	Recruitment in the actinomycin-eluting stent improves outcomes by reducing neointimal hyperplasia.
Angiopeptin	SWAN	Stent with angiopeptin.
Medtronic ABT-578	ENDEAVOR I–III	A randomized controlled trial to evaluate the safety and efficacy of the Medtronic AVE ABT-578- eluting driverTM coronary stent in de novo native coronary artery lesions
Abbott ABT-578	Zomaxx 1	Zomaxx coronary drug-eluting stent for de novo lesion in coronary arteries.
Estradiols	EASTER	Estrogen and stent to eliminate restenosis.
NO donor compounds	NOBLESSE	Nitric oxide through a biodegradable layer elective study for safety and efficacy.
EPC antibodies	HEALING I–II	Healthy endothelial accelerated lining inhibits neointimal growth.

MPA: mycophenolic acid, PC: phosphorylcholine, and SV: small vessel.